JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

Search

IQVIA Holdings Inc

Open

SectorHealthcare

155.45 -1.57

Overview

Share price change

24h

Current

Min

153.65

Max

159.59

Key metrics

By Trading Economics

Income

182M

514M

Sales

264M

4.4B

P/E

Sector Avg

20.898

67.147

Profit margin

11.778

Employees

93,000

EBITDA

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+41.24% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2026

Market Stats

By TradingEconomics

Market Cap

-12B

28B

Previous open

157.02

Previous close

155.45

News Sentiment

By Acuity

50%

50%

201 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 kwi 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 kwi 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 kwi 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 kwi 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 kwi 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 kwi 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 kwi 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 kwi 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 kwi 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 kwi 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 kwi 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 kwi 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

41.24% upside

12 Months Forecast

Average 224.54 USD  41.24%

High 255 USD

Low 185 USD

Based on 16 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

201 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat